MapLight Therapeutics, Inc. (MPLT): Operating Income
-$169.08M
Year ended 2025-12-31
-$242.93M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$169.08M | n/m | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | -$82.95M | n/a | 2026-03-26, From 2024-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) | 2025-12-31 | -$169.08M | n/m |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | -$192.02M | n/m |
| Enliven Therapeutics, Inc. (ELVN) | 2025-12-31 | -$119.66M | n/m |
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | -$122.05M | n/a |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | -$151.17M | n/m |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | -$40.98M | n/m |
| Biohaven Ltd. (BHVN) | 2025-12-31 | -$745.38M | n/m |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | -$125.10M | n/m |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | -$145.82M | n/m |
Compare MPLT, RYTM, ELVN, ORKA side by side · Screen every company in Pharmaceutical Preparations ↗